ArticleEuropean journal of pediatrics2026
Exertional leg pain in pediatric familial mediterranean fever: clinical associations and implications for treatment.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exertional leg pain (ELP) is a common but frequently underrecognized symptom in children with familial Mediterranean fever (FMF). This study aimed to evaluate the clinical characteristics of ELP, its relationship with disease severity, and its potential impact on treatment modifications in a large pediatric cohort. This study evaluated pediatric FMF patients (2013-2024) fulfilling the 2019 Eurofever/PRINTO criteria. Demographic, clinical, genetic, and treatment data were analyzed. Disease severity was assessed using the International Severity Score for FMF (ISSF). Among 1290 patients, 464 (36.0%) experienced ELP. Patients with ELP were diagnosed at a younger age and had a longer follow-up duration (p = 0.005 and p < 0.001). ELP was significantly associated with arthralgia (p < 0.001), arthritis (p = 0.003) and erysipelas-like erythema (p = 0.01). According to the ISSF, patients with ELP had higher disease severity scores and a higher frequency of moderate-to-severe disease (p = 0.007). Homozygous M694V mutations and colchicine resistance were more frequent in the ELP group (both p < 0.001) and multivariate analysis identified M694V homozygosity, longer follow-up duration, and higher disease severity as independent predictors of ELP. Treatment modifications were required in 68 (14.6%) patients with ELP, most commonly involving colchicine dose escalation or nonsteroidal anti-inflammatory drugs. Further evaluation revealed sacroiliitis in 6 (1.3%) patients and chronic nonbacterial osteomyelitis (CNO) in 2 (0.4%) patients.
conclusionELP is associated with increased disease severity and colchicine resistance in pediatric FMF and may influence treatment decisions, particularly in patients with conditions like sacroiliitis or CNO. Systematic assessment of ELP provides insight into disease characteristics and helps identify patients with a more challenging disease course. WHAT IS KNOWN: • Exertional leg pain is a recognized musculoskeletal manifestation of familial Mediterranean fever. • It has been associated with arthritis, enthesopathy, and a more severe disease phenotype. WHAT IS NEW: • In a large pediatric cohort, exertional leg pain was associated with increased disease severity, colchicine resistance, homozygous M694V mutations, and was more frequent in patients with erysipelas-like erythema and lower-extremity arthritis. • Recognition of exertional leg pain influenced treatment decisions and occasionally prompted evaluation for sacroiliitis or chronic nonbacterial osteomyelitis.
Indexed as
Identifiers
42050020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.